Drugs / KBP-COVID-19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04473690 | Dec 2020 → May 2022 | COVID-19 | KBio Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBP-COVID-19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04473690 ↗ |
| Modality | Vaccine | “KBP-COVID-19 plus CPG adjuvant vaccine” NCT04473690 ↗ |
| Route | Intramuscular | “receive study vaccine or placebo by IM injection on Days 1 and 22” NCT04473690 ↗ |